N. Amin

发表

Pharmacokinetics, mass balance, metabolism, and excretion of the liver-targeted acetyl-CoA carboxylase inhibitor PF-05221304 (clesacostat) in humans

A. Kalgutkar, A. Bergman, T. E. Ballard, 2022, Xenobiotica; the fate of foreign compounds in biological systems.

Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

G. Nucci, R. Boyd, V. Sahasrabudhe, 2020, Clinical Pharmacokinetics.

Metabolism and Excretion of the Anti-Diabetic Agent Ertugliflozin ( PF-04971729 ) in Healthy Male Subjects

G. Nucci, A. Kalgutkar, A. Vaz, 2012 .

Two dose‐ranging studies with PF‐04937319, a systemic partial activator of glucokinase, as add‐on therapy to metformin in adults with type 2 diabetes

W. S. Denney, G. Paragh, D. Páll, 2015, Diabetes, obesity & metabolism.

ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials

M. Inglot, T. Tuthill, J. Pfefferkorn, 2021, Nature Medicine.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver‐Targeting Acetyl‐CoA Carboxylase Inhibitor (PF‐05221304): A Three‐Part Randomized Phase 1 Study

S. Tarabar, A. Bergman, W. Esler, 2020, Clinical pharmacology in drug development.

Blood pressure‐lowering effect of the sodium glucose co‐transporter‐2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension

G. Nucci, X. Wang, N. Amin, 2015, Diabetes, obesity & metabolism.

Metabolites in Safety Testing Assessment in Early Clinical Development: A Case Study with a Glucokinase Activator

W. S. Denney, A. Kalgutkar, J. Pfefferkorn, 2014, Drug Metabolism and Disposition.

Safety, tolerability, pharmacokinetics and pharmacodynamics of a liver-targeting ACC inhibitor (PF-05221304) following single and multiple oral doses

S. Tarabar, A. Bergman, W. Esler, 2018 .

Dose‐ranging efficacy and safety study of ertugliflozin, a sodium‐glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin

G. Nucci, X. Wang, N B Amin, 2015, Diabetes, obesity & metabolism.

Pharmacokinetics, Metabolism, and Excretion of the Antidiabetic Agent Ertugliflozin (PF-04971729) in Healthy Male Subjects

Zhuang Miao, Ernesto Callegari, Gianluca Nucci, 2013, Drug Metabolism and Disposition.

Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology.

V. Somayaji, A. Saxena, N. Amin, 2023, Clinical therapeutics.

Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis

B. Goodwin, Tong Zhu, S. Carvajal-Gonzalez, 2019, Science Translational Medicine.

Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF‐04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin—A Randomized, Crossover, Active‐Controlled Study

W. S. Denney, M. Riggs, N. Amin, 2016, Clinical pharmacology in drug development.

Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients.

A. Besarab, S. Frinak, Ajay Gupta, 2000, Journal of the American Society of Nephrology : JASN.

Pharmacokinetics, Metabolism, and Excretion of the Antidiabetic Agent Ertugliflozin (PF-04971729) in Healthy Male Subjects

G. Nucci, A. Kalgutkar, A. Vaz, 2013, Drug Metabolism and Disposition.